The total number of records retrieved from this search are 67. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3738	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell line22RV1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c-rag and gamma negative xenograft for 22Rv1 (2.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultRegression in tumor volume to 0.4 cm after day 80	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3739	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell line22RV1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c-rag and gamma negative xenograft for 22Rv1 (2.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor after day 80	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3740	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineVCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c-rag and gamma negative xenograft for VCap (2.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultRegression in tumor volume to 0.3 cm after day 80	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3771	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3772	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume to below 500mm after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3773	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990/Gemcitabine resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3774	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990/Gemcitabine resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW1990	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume to below 300mm after 56 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_4083	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus encoded with drosophila dNK gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug DFDC(10mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MCF7 (1.0E+7)	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultVirus and drug prolongs the mice survival and reduction in tumor volume to 1000mm compared to control 3000mm after 60 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID26203222
IDOV_4204	Virus nameAdenovirus	Virus strainAd-CXCR4-DAL1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing DAL-1 gene under promoter CXXR4	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice subcutaneously xenograft for A549 cell (2.0E+6)	In-vivo virus concentration1.0E+9 pfu, every other day for 3 times	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 1.5 centimeter cube after 28 days compared to control 7 centimeter cube	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4225	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 21 days in mice 1 and increase in PFS above 200 days compared to control 75 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4226	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 42 days in mice 2 and increase in PFS above 200 days compared to control 75 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4227	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 49 days in mice 3 and increase in PFS above 200 days compared to control 75 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4228	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 56 days in mice 4 and increase in PFS above 200 days compared to control 75 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4229	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for IMR-32 (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 100 cubic millimetet after 70 days in mice 1 and increase in PFS above 200 days from 150 days to control	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4230	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for IMR-32 (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 49 days in mice 2 and increase in PFS above 200 days from 150 days to control	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4231	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for IMR-32 (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 49 days in mice 3 and increase in PFS above 200 days from 150 days to control	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4232	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for IMR-32 (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 56 days in mice 4 and increase in PFS above 200 days from 150 days to control	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4233	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for IMR-32 (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 56 days in mice 5 and increase in PFS above 200 days from 150 days to control	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4234	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for IMR-32 (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 70 days in mice 6 and increase in PFS above 200 days from 150 days to control	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4235	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 1000 cubic millimeter in mice 1 after 56 days	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4236	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 28 days in mice 2	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4237	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 28 days in mice 3	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4238	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 28 days in mice 4	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4239	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 48 days in mice 5	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4240	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 56 days in mice 6	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4241	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c AnNcrj-nu/nu female mice xenograft for SK-N-SH (1.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 56 days in mice 7	Mode of deliveryIntravenous	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4364	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 8-CPT-cAMP (20mg/kg/day)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice subcutaneous xenograft for HCT-116 (5.0E+6)	In-vivo virus concentration3.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 0.4 cubic centimeter after 22 days compared to control 1.2 cubic centimeter	Mode of deliveryIntravenous	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4365	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 8-CPT-cAMP (20mg/kg/day)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice subcutaneous xenograft for Hep3B (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 1.5 cubic centimeter after 22 days compared to control 7.5 cubic centimeter	Mode of deliveryIntravenous	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4366	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 8-CPT-cAMP (20mg/kg/day)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice subcutaneous xenograft for Capan-1 (1.0E+7)	In-vivo virus concentration3.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 0.2 cubic centimeter after 22 days compared to control 0.8 cubic centimeter	Mode of deliveryIntravenous	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4603	Virus nameAdenovirus	Virus strainCD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for A549 cell (5.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 300 cubic mm comapred to control 700 cubic mm after 40 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4604	Virus nameAdenovirus	Virus strainCD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for A549 cell (5.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 220 cubic mm comapred to control 700 cubic mm after 40 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4605	Virus nameAdenovirus	Virus strainCD55-TRAIL+ CD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIl and MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for A549 cell (5.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 200 cubic mm comapred to control 700 cubic mm after 40 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4606	Virus nameAdenovirus	Virus strainCD55-TRAIL-IETD-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having TRAIL, MnSOD gene linked via IETD caspase 8 cleavage site	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for A549 cell (5.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 100 cubic mm comapred to control 700 cubic mm after 40 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_5223	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for H1299 (2.0E+6 cells)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultNo significant reduction in tumor volume compared to control	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5224	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for H1299 (2.0E+6 cells)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultNo significant reduction in tumor volume compared to control	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5225	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for H1299 (2.0E+6 cells)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 1000 cubic mm after 35 days compared to control 6000 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5226	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SKOV3 (2.0E+6 cells)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 2500 cubic mm after 45 days compared to control 3500 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5227	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SKOV3 (2.0E+6 cells)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 2500 cubic mm after 45 days compared to control 3500 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5228	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SKOV3 (2.0E+6 cells)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 800 cubic mm after 45 days compared to control 3500 cubic mm	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5229	Virus nameParovirus	Virus strainwild type	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 4T1 (1.0E+5 cells)	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor volume 700 cubic mm compared to control 1700 cubic mm after 33 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectIncrease production of IFN-gama and IL-2	Clinical trialNA	PMID27776794
IDOV_5230	Virus nameParovirus	Virus strainwild type	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 4T1 (1.0E+5 cells)	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor volume 4200 cubic mm compared to control 1700 cubic mm after 33 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectIncrease production of IFN-gama and IL-2	Clinical trialNA	PMID27776794
IDOV_5332	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with DTIC 100 microgram per ml	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A375 (2.0E+6)	In-vivo virus concentration10 MOI	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 250 cubic mm after six week compared to control 800 cubic mm	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5333	Virus nameHerpes simplex virus	Virus strainHSV2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for ICP34.5 and ICP47 gene and insertion of GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing GMCSF gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for CT26 (5.0E+5)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume 1200 cubic mm compared to control 2500 cubic mm after 28 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectInduce prolifration of tumor specific T cell	Clinical trialNA	PMID28223815
IDOV_5357	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 3.0E+5 MIAPaCa2	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 1700 cubic mm after 60 days compared to 2700 cubic mm	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5358	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 5.0E+5 BxPC3	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 1000 cubic mm after 60 days compared to 2700 cubic mm	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5359	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 5.0E+5 PANC1	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 400 cubic mm after 60 days compared to 1000 cubic mm	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5360	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine 1.5mg/kg	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 3.0E+5 MIAPaCa2	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 500 cubic mm after 60 days compared to 2700 cubic mm	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5361	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine 1.5mg/kg	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 5.0E+5 BxPC3	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 400 cubic mm after 60 days compared to 2700 cubic mm	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5362	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine 1.5mg/kg	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for 5.0E+5 PANC1	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 100 cubic mm after 60 days compared to 1000 cubic mm	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5368	Virus nameHerpes simplex virus	Virus strainHF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice isograft for 1.0E+6 MC26 cells	In-vivo virus concentration1.0E+7 pfu on day 10, 17 and 24	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 500 mm compared to control 2500 mm after 28 days and increase in survival time	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectStimulation of cytotoxic CD8 T cells	Clinical trialNA	PMID28331843
IDOV_5381	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice isograft for 2.0E+5 4T1 cells	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 400 cubic mm compared to control 800 cubic mm after 25 days and increase in survival time to 45 days compared to 40 days control	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectLevel of IFN beta production does not effected by combination	Clinical trialIn clinical trial for various cancer cell line	PMID27503504
IDOV_5382	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice isograft for 2.0E+5 EMT6 cells	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 800 cubic mm compared to control 1000 cubic mm after 18 days and increase in survival time to 30 days compared to 25 days control	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectLevel of IFN beta production does not effected by combination	Clinical trialIn clinical trial for various cancer cell line	PMID27503504
IDOV_5384	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 2mg/kg micromolar palcitaxel for 48 hours	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice isograft for 2.0E+5 4T1 cells	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 200 cubic mm compared to control 800 cubic mm after 25 days and increase in survival time to 60 days compared to 40 days control	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectLevel of IFN beta production does not effected by combination	Clinical trialIn clinical trial for various cancer cell line	PMID27503504
IDOV_5385	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 10mg/kg micromolar palcitaxel for 48 hours	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice isograft for 2.0E+5 EMT6 cells	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 400 cubic mm compared to control 1000 cubic mm after 18 days and increase in survival time to 30 days compared to 25 days control	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectLevel of IFN beta production does not effected by combination	Clinical trialIn clinical trial for various cancer cell line	PMID27503504
IDOV_5457	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice injected with tumor	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultMice failed to develop cancer	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS41098983
IDOV_5458	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice injected with tumor	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultMice failed to develop cancer	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS41098983
IDOV_5459	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice injected with tumor	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultMice failed to develop cancer	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS41098983
IDOV_5484	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 2%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5485	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 5%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5510	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 2%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5511	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 5%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5536	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 2%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5537	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 5%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5673	Virus nameAdenovirus	Virus strainOV802	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for A549 (5.0E+6 )	In-vivo virus concentration4.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 300 after 80 days	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of IFN-Gamma, IL6 and other immunostimulatory cytokines production	Clinical trialNA	PMIDUS7473418
IDOV_5883	Virus nameParovirus	Virus strainMutant	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationDeletion mutatnt for Gamma 34.5, ICP6 and ICP47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for PANC-1	In-vivo virus concentration1 RU per ml	In-vivo toxicityNA	In-vivo resultTumor volume reduced to 500mm after 83 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8916176
IDOV_5884	Virus nameParovirus	Virus strainMutant	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationDeletion mutatnt for Gamma 34.5, ICP6 and ICP47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeYes	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for HeLa (2.0E+6)	In-vivo virus concentration1 RU per ml	In-vivo toxicityNA	In-vivo resultSurvival time increased up to 40 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8916176
IDOV_5914	Virus nameNewcastle disease virus	Virus strainNDV-F3aa	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus expressing NS1 protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for B16-F10 (1.0E+5)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 25 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectVirus induced IFN-gamma production	Clinical trialNA	PMIDUS10035984